This paper is in the following e-collection/theme issue:

Theme Issue: Novel Coronavirus (COVID-19) Outbreak Rapid Reports (1520) Drug Repurposing and Off-Label Use (25) JMIR Theme Issue: COVID-19 Special Issue (2461) Viewpoints and Perspectives (525)

Published on in Vol 6, No 2 (2020): Apr-Jun

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/19199, first published .
Delivering Benefits at Speed Through Real-World Repurposing of Off-Patent Drugs: The COVID-19 Pandemic as a Case in Point

Delivering Benefits at Speed Through Real-World Repurposing of Off-Patent Drugs: The COVID-19 Pandemic as a Case in Point

Delivering Benefits at Speed Through Real-World Repurposing of Off-Patent Drugs: The COVID-19 Pandemic as a Case in Point

Authors of this article:

Moshe Rogosnitzky1 Author Orcid Image ;   Esther Berkowitz1 Author Orcid Image ;   Alejandro R Jadad2, 3 Author Orcid Image
Article Authors Cited by (33) Tweetations (391) Metrics

Journals

  1. Pillaiyar T, Wendt L, Manickam M, Easwaran M. The recent outbreaks of human coronaviruses: A medicinal chemistry perspective. Medicinal Research Reviews 2021;41(1):72 View
  2. Infante M, Ricordi C, Alejandro R, Caprio M, Fabbri A. Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection. Expert Review of Anti-infective Therapy 2021;19(1):5 View
  3. Mostafa T. Could Oral Phosphodiesterase 5 Inhibitors Have a Potential Adjuvant Role in Combating COVID-19 Infection?. Sexual Medicine Reviews 2021;9(1):15 View
  4. Lisi L, Lacal P, Barbaccia M, Graziani G. Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2. Biochemical Pharmacology 2020;180:114169 View
  5. Heffernan K, Ranadive S, Jae S. Exercise as medicine for COVID-19: On PPAR with emerging pharmacotherapy. Medical Hypotheses 2020;143:110197 View
  6. Mondaini N. Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management?. The World Journal of Men's Health 2020;38(3):254 View
  7. Cadegiani F. Repurposing existing drugs for COVID-19: an endocrinology perspective. BMC Endocrine Disorders 2020;20(1) View
  8. Tyagi S, Singh M. Multi-organ damage by covid-19: congestive (cardio-pulmonary) heart failure, and blood-heart barrier leakage. Molecular and Cellular Biochemistry 2021;476(4):1891 View
  9. Ennis M, Tiligada K. Histamine receptors and COVID-19. Inflammation Research 2021;70(1):67 View
  10. Yeramaneni S, Doshi P, Sands K, Cooper M, Kurbegov D, Fromell G. Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System. Gastroenterology 2021;160(3):919 View
  11. Rios C, Cassatt D, Hollingsworth B, Satyamitra M, Tadesse Y, Taliaferro L, Winters T, DiCarlo A. Commonalities Between COVID-19 and Radiation Injury. Radiation Research 2020;195(1) View
  12. Rogosnitzky M, Berkowitz E, Jadad A. No Time to Waste: Real-World Repurposing of Generic Drugs as a Multifaceted Strategy Against COVID-19. JMIRx Med 2020;1(1):e19583 View
  13. Reznikov L, Norris M, Vashisht R, Bluhm A, Li D, Liao Y, Brown A, Butte A, Ostrov D. Identification of antiviral antihistamines for COVID-19 repurposing. Biochemical and Biophysical Research Communications 2021;538:173 View
  14. Motta N, Autran L, Brazão S, Lopes R, Scaramello C, Lima G, Brito F. Could cilostazol be beneficial in COVID-19 treatment? Thinking about phosphodiesterase-3 as a therapeutic target. International Immunopharmacology 2021;92:107336 View
  15. Dabbish A, Yonis N, Salama M, Essa M, Qoronfleh M. Inflammatory pathways and potential therapies for COVID-19: A mini review. European Journal of Inflammation 2021;19 View
  16. Kifle Z, Ayele A, Enyew E, Broecker F. Drug Repurposing Approach, Potential Drugs, and Novel Drug Targets for COVID-19 Treatment. Journal of Environmental and Public Health 2021;2021:1 View
  17. Caiazza R, Phan P, Lehmann E, Etzkowitz H. An absorptive capacity-based systems view of Covid-19 in the small business economy. International Entrepreneurship and Management Journal 2021;17(3):1419 View
  18. Pawar A, Pal A, Goswami K, Squitti R, Rongiolettie M. Molecular basis of quercetin as a plausible common denominator of macrophage-cholesterol-fenofibrate dependent potential COVID-19 treatment axis. Results in Chemistry 2021;3:100148 View
  19. Davies S, Mycroft-West C, Pagani I, Hill H, Chen Y, Karlsson R, Bagdonaite I, Guimond S, Stamataki Z, De Lima M, Turnbull J, Yang Z, Vicenzi E, Skidmore M, Khanim F, Richardson A. The Hyperlipidaemic Drug Fenofibrate Significantly Reduces Infection by SARS-CoV-2 in Cell Culture Models. Frontiers in Pharmacology 2021;12 View
  20. Richman S, Lyman C, Nesterova A, Yuryev A, Morris M, Cao H, Cheadle C, Skuse G, Broderick G. Old drugs, new tricks: leveraging known compounds to disrupt coronavirus-induced cytokine storm. npj Systems Biology and Applications 2022;8(1) View
  21. Basnet R, Khadka S, Basnet B, Basnet T, Sapkota S. Overview of Drug Therapy of COVID-19 with Safety and the Potential Clinical Benefits. Current Drug Therapy 2022;17(5):327 View
  22. Shafiekhani M, Dehghani A, Shahisavandi M, Nabavizadeh S, Kabiri M, Hassani A, Haghpanah A. Pharmacotherapeutic approach toward urological medications and vaccination during COVID-19: a narrative review. Therapeutic Advances in Urology 2021;13 View
  23. Mahdiraji H, Kamardi A, Beheshti M, Hajiagha S, Rocha-Lona L. Analysing supply chain coordination mechanisms dealing with repurposing challenges during Covid-19 pandemic in an emerging economy: a multi-layer decision making approach. Operations Management Research 2022;15(3-4):1341 View
  24. Shamohammadi I, Kazemeyni S, Sadighi M, Hasanzadeh T, Dizavi A. Efficacy of tadalafil on improvement of men with erectile dysfunction caused by COVID-19: A randomized placebo-controlled trial. Asian Journal of Urology 2024;11(1):128 View
  25. Lim S, Murphy S, Murphy S, Coughlan T, O'Neill D, Tierney S, Egan B, Collins D, McCarthy A, Lim S, Smith D, Cox D, McCabe D. Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke. Journal of the Neurological Sciences 2022;441:120334 View
  26. Jash R, Prasanth D, Jash M, Suneetha A. Small molecules in the race of COVID-19 drug development. Journal of Asian Natural Products Research 2023;25(12):1133 View
  27. Ataei M, Arasteh O, Maghsoudi A, Hassani S, Hosseinjani H. Therapeutic uses of Antihistamines in the Management of COVID-19: A Narrative Review. Anti-Infective Agents 2023;21(2) View
  28. Manchanda R, Miglani A, Kalsi A, Brahmachari S, Rama K, Goel P, Kaushik P, Jethani A, Nagrath C, Pangtey N, Kannoth J, Sharma K, Arora S, Amitav B, Roy P, Kudiyarasu R, Rutten L. Homeopathic Medicines in Third (Omicron) Wave of COVID-19: Prognostic Factor Research. Homeopathy 2024;113(04):223 View
  29. Chakraborty A, Ghosh R, Soumya Mohapatra S, Barik S, Biswas A, Chowdhuri S. Repurposing of antimycobacterium drugs for COVID-19 treatment by targeting SARS CoV-2 main protease: An in-silico perspective. Gene 2024;922:148553 View
  30. Takura T, Yokoi H, Honda A. Factors Influencing Drug Prescribing for Patients With Hospitalization History in Circulatory Disease–Patient Severity, Composite Adherence, and Physician-Patient Relationship: Retrospective Cohort Study. JMIR Aging 2024;7:e59234 View

Books/Policy Documents

  1. Mohanty C, Vinod C, Acharya S, Mahapatra N. Modeling, Control and Drug Development for COVID-19 Outbreak Prevention. View
  2. Rogosnitzky M. Drug Repurposing. View
  3. Altuntas F. Using Crises and Disasters as Opportunities for Innovation and Improvement. View